In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
Purpose Liposomal cisplatin was developed to reduce the systemic toxicity of cisplatin , particularly the nephrotoxicity , and it has been used in combination with other agents in pancreatic and head and neck cancers and non-small-cell lung cancer ( NSCLC ) . Our objective was to compare the effectiveness of lipoplatin combined with paclitaxel versus cisplatin with paclitaxel in advanced non-squamous NSCLC . Methods During 2007–2010 , 202 patients with non-squamous NSCLC ( stage IIIB and IV ) were recruited from the two participating institutions and divided into two arms : Arm A was treated with liposomal cisplatin 200 mg/m2 combined with paclitaxel 135 mg/m2 and Arm B with cisplatin 75 mg/m2 in combination with paclitaxel 135 mg/m2 , repeated every 2 weeks . The number of cycles administered was 632 ( Arm A ) and 640 ( Arm B ) , totaling 1,272 . Results A partial response was achieved by 59.22 % of Arm A patients versus 42.42 % of Arm B , and the difference was statistically significant ( P 0.036 ) . The median survival time in months was 10 for Arm A and 8 for Arm B ( P 0.1551 ) . After 18 months , the number of surviving patients was double for Arm A versus Arm B. Conclusion Liposomal cisplatin in combination with paclitaxel produces a statistically significantly higher response rate than cisplatin combined with paclitaxel in non-squamous NSCLC
In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .